These researchers and specialists were hopeful regarding both precision medicine and more innovative trial designs (in order to effectively deliver new Alzheimer\u2019s treatments). Based on these approaches, two experimental drugs may effectively treat some patients living with Alzheimer\u2019s. <\/span><\/p>\n Currently, most available treatments (regardless of the condition or disease), treat the \u00abaverage\u00bb patient. However, since each individual patient is unique in terms of their genetics and physiology, not all treatments are one-size-fits-all. <\/span><\/p>\n Precision medicine, on the other hand, is an approach that matches each patient with the best possible treatment for them and their needs. Also known as individualized or personalized medicine, this treatment takes many variables into account, including one\u2019s lifestyle, environment, genetics, and even the impact of certain microbes.<\/span><\/p>\n As stated in <\/span>one review<\/span><\/a>, published in the <\/span>Annals of Translational Medicine<\/span><\/i>, in recent years, significant advances have been made in precision medicine. This is particularly true for select cancers and cystic fibrosis. However, for most diseases, including Alzheimer\u2019s, precision medicine is in its earliest stages. <\/span><\/p>\n To advance this area of medicine, governments around the globe are launching Precision Medicine Initiatives. Since the risk and molecular profiles of people with Alzheimer\u2019s show immense variation, precision medicine may be an effective solution. By identifying each patient\u2019s specific pattern of risk factors,\u00a0this may lead to a more personalized approach.\u00a0<\/span><\/p>\n Most recently, two experimental drugs benefited some patients with Alzheimer\u2019s. The first, <\/span>BAN2401<\/span><\/a>, was shown to dramatically reduce amyloid plaque deposits in the brains of Alzheimer\u2019s patients. In fact, after 18 months, those who received the highest dose showed a 26 percent slowing of clinical decline in comparison to the placebo group. <\/span><\/p>\n In this case,\u00a0the trial’s \u201cadaptive design\u201d ensured that the latest patients were assigned to groups that showed the greatest promise. Although this is controversial among some researchers, most agree that Alzheimer\u2019s trials need to evolve. By trying new approaches, new targeted therapies could develop. <\/span><\/p>\n Related<\/strong>: <\/span>A Promising Study Brings Hope for a Potential Alzheimer\u2019s Treatment<\/span><\/a><\/p>\n The second drug, known as Anavex 2-73, was recently studied in patients who display a few actionable genetic variants. This means these patients can potentially take preventative action in order to significantly reduce their risk of a genetic-related disease. <\/span><\/p>\n Although this trial was small, it was unique in that researchers sequenced the patients\u2019 genomes. They hoped to find key genomic signatures that would make them more likely to respond to certain drugs. After identifying more than 33,000 genes, the researchers had a good idea of how <\/span>Anavex 2-73<\/span><\/a> impact specific molecular processes.\u00a0<\/span><\/p>\n This resulted in a trial that included a narrowed subject pool. After receiving this drug for 57 weeks, those who displayed the targeted genetic variants showcased clinically meaningful improvements. These improvements included their ability to remember, reason, and carry out daily activities. <\/span><\/p>\n As reported in <\/span>a recent press release<\/span><\/a>, precision medicine may also support sex and gender differences in regards to Alzheimer\u2019s. Since more\u00a0women suffer from Alzheimer’s than men, precision medicine could help target genetic and biological differences. <\/span><\/p>\n Gender and sex differences, including genetic and psychosocial domains,\u00a0may be highly relevant in regards to the development and progression of Alzheimer\u2019s. If researchers are able to identify key biomarkers, this would have a positive impact on the design of clinical therapy trials \u2014 especially in terms of precision medicine. <\/span><\/p>\nWhat Is Precision Medicine?<\/span><\/h1>\n
The Introduction of BAN2401 and Anavex 2-73<\/span><\/h2>\n
Precision Medicine May Support Sex Differences <\/span><\/h3>\n
The BrainTest\u00ae App Is a Supportive Assessment Tool<\/span> <\/span><\/h2>\n
![\"\"](\"http:\/\/braintest.com\/wp-content\/uploads\/ipad-braintest.png\")
<\/a><\/p>\n